Details

Autor(en) / Beteiligte

• Panzuto, Francesco
• Rinzivillo, Maria
• Spada, Francesca
• Antonuzzo, Lorenzo
• Ibrahim, Toni
• Campana, Davide
• Fazio, Nicola
• Delle Fave, Gianfranco

Titel

Everolimus in Pancreatic Neuroendocrine Carcinomas G3

Ist Teil von

• Pancreas, 2017-03, Vol.46 (3), p.302-305

Ort / Verlag

United States

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• The aim of this study was to investigate everolimus efficacy in well-moderately differentiated pancreatic NEC (pNEC) G3. This was a retrospective analysis of patients with pNEC G3 and Ki67 20% to 55% treated with everolimus. Fifteen patients with median Ki67 30% and Eastern Cooperative Oncology Group performance status 0 to 1 were evaluated. Of these, 4 patients received everolimus as first-line treatment, whereas 11 had been pretreated with chemotherapy or peptide receptor radionuclide therapy. Median progression-free survival was 6 months, and median overall survival was 28 months. Eleven patients achieved disease stabilization (DS) at 3 month follow-up. Six patients (40%) maintained DS for at least 12 months. Three of 4 patients who received everolimus as first-line therapy had sustained DS (progression-free survival, 12, 17, and 22 months). The safety profile was consistent with that previously reported, with adverse events occurring in 9 patients (66.7%). This study suggests that everolimus is active in pNEC G3 with well-moderately differentiated morphology and Ki67 less than 55%, in which more toxic systemic chemotherapy is, to date, the only available treatment.